FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/25/2026
Back to search
Official data from USPTO
ALCHEMAB
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ALCHEMAB
ST13
US500000079403954Class
5, 9, 42, 44
Filing
79403954
Registration
8026498
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
33
Latest update
06/25/2026
Trademark type
Word
Nice classes
5, 9, 42, 44
Filing date
07/03/2024
Registration date
11/18/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/18/2025
Last transaction
06/25/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
MEYERS, MORGAN LAURA
Law office
L40
Current location
TMEG LAW OFFICE 104
Holders and representatives
Holders
Alchemab Therapeutics Ltd
Alchemab Therapeutics Ltd
Representatives
James M. Theo Dinsmore & Shohl LLP
Technical classification
Nice Classes
Class 5Class 9Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; pharmaceutical preparations incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; chemical preparations for medical and pharmaceutical purposes incorporating antibodies for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; Chemical preparations for medical and pharmaceutical purposes incorporating antibody technology for the treatment of neurological and neurodegenerative diseases and disordersmetabolic diseases and disordersimmunological diseases and disordersoncological diseases and disordersAmyotrophic Lateral Sclerosis (ALS)muscle atrophyParkinson's disease and Alzheimer's disease; antibodies for medical purposes; diagnostic preparations involving the testing and identification of antibodies for medical purposes; diagnostic preparations involving the testing of antibodies for medical purposes; diagnostic preparations involving the identification of antibodies for medical purposes.
Class 9
Downloadable software for the testing of antibodies; downloadable software for the identification of antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibodies; downloadable software for use in development of pharmaceutical preparations incorporating antibody technology.
Class 42
Research and development services in the field of antibodies and antibody technology; drug development and discovery services in relation to pharmaceutical preparations incorporating antibodies and antibody technology; antibody discovery services in the nature of drug discovery services; development and testing of computing methodsalgorithms and software for the testing and identification of antibodies; development and testing of computing methodsalgorithms and software in the field of antibody technology; development and testing of computing methodsalgorithms and software for use in or relating to the development of pharmaceutical preparations incorporating antibodies and antibody technology; informationadvisory and consultancy services in relation to all of the aforesaid.
Class 44
Medical diagnostic services involving the testing of antibodies for medical purposes; medical diagnostic services involving the identification of antibodies for medical purposes; medical testinganalysis and diagnostic services in the field of antibodies; informationadvisory and consultancy services in relation to all of the aforesaid.
Publications
History of USPTO decisions and trademark events.
33 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/04/2026
FIMP
FINAL DISPOSITION PROCESSED
06/04/2026
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
04/14/2026
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
03/23/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/09/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
02/19/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/18/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/04/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/04/2026
ES7R
TEAS SECTION 7 REQUEST RECEIVED
12/09/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/18/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
11/18/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/30/2025
PUBO
PUBLISHED FOR OPPOSITION
09/30/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/24/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/28/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
08/28/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/28/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
08/28/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/28/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/06/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/06/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/06/2025
RFNT
REFUSAL PROCESSED BY IB
03/22/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/04/2025
RFRR
REFUSAL PROCESSED BY MPU
03/04/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/16/2025
CNRT
NON-FINAL ACTION WRITTEN
01/15/2025
DOCK
ASSIGNED TO EXAMINER
12/28/2024
MAFR
APPLICATION FILING RECEIPT MAILED
09/09/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/09/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/05/2024
Continuous trademark protection
Get notified about every new filing that threatens ALCHEMAB or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.